Daily non-political popular news in brief.
Promising results from first gene therapy clinical trial for Parkinson's disease reported
06-21-2007 · EurekAlert!In what could be a breakthrough in the treatment of neurological disease, a team led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has completed the first-ever phase 1 clinical trial using gene therapy to battle Parkinson's disease.
Read more »
Keywords: promising, results, gene, therapy, clinical, trial, parkinson, disease, reported, result
« Previous | Next »
Similar news on "Promising results from first gene therapy clinical trial for Parkinson's disease reported":
- Gene therapy study shows safety and statistically significant improvement in Parkinson's disease
06-21-2007 · EurekAlert!
The first gene therapy trial for Parkinson's disease, an open label Phase 1 study in 12 patients with advanced disease, demonstrated both a lack of adverse events and statistically significant improvements from baseline in both clinical symptoms and abnormal brain metabolism (as measured by positron emission tomography, or PET scanning).
Similar news · Read more »
- Promising Antiobesity Drug Fails To Produce Clinically Meaningful Weight Loss
10-05-2006 · ScienceDaily
A drug designed to target a powerful hunger-stimulating factor that has long been considered a prime target for antiobesity therapy failed to produce clinically meaningful weight loss in obese people in a long-term clinical trial. People taking the drug known as MK-0557 for a year consistently lost about three pounds more than those taking a placebo, researchers reported in the October issue of the journal Cell Metabolism, published by Cell Press.
Similar news · Read more »
- Multiple myeloma clinical trial shows distinct survival benefit with lower dose of steroids
12-09-2007 · EurekAlert!
Results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03, for multiple myeloma, showing significantly better overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone, were reported today by S. Vincent Rajkumar, MD, at the American Society of Hematology's annual meeting.
Similar news · Read more »
- Vaxfectin-formulated measles DNA vaccine elicits long-term protection in nonhuman primates
05-31-2007 · EurekAlert!
Diane Griffin, M.D., Ph.D., of Johns Hopkins University Bloomberg School of Public Health will be presenting findings on Thursday, May 31 at the 10th Annual American Society of Gene Therapy meeting in Seattle showing that an experimental measles DNA vaccine showed promising results in infant monkeys and achieved "sterilizing immunity," or near-complete eradication of disease, in juvenile monkeys. The studies were conducted under a grant from the Bill and Melinda Gates Foundation.
Similar news · Read more »
- First clinical trial of gene therapy for childhood blindness
05-01-2007 · EurekAlert!
The first clinical trial to test a revolutionary treatment for blindness in children has been announced by researchers at UCL (University College London). The trial, funded by the Department of Health, is the first of its kind and could have a significant impact on future treatments for eye disease.
Similar news · Read more »
- MIT radar technology fights breast cancer
11-27-2007 · EurekAlert!
Treating breast cancer with a type of heat therapy derived from MIT radar research can significantly increase the effectiveness of chemotherapy, according to results from the fourth clinical trial of the technique reported online Nov. 25 in the journal Cancer Therapy.
Similar news · Read more »
- Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
09-04-2007 · EurekAlert!
The results of a clinical trial, published in late August in the Journal of Pediatrics, indicates that, when used as part of routine therapy, high-dose ibuprofen is safe and effective in slowing down lung disease in children with cystic fibrosis (CF).
Similar news · Read more »
- Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
10-03-2007 · EurekAlert!
The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index.
Similar news · Read more »
- Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia
06-02-2007 · EurekAlert!
An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a phase II clinical trial at the University of Texas M. D. Anderson Cancer Center.
Similar news · Read more »
- Treating HIV-infected infants early helps them live longer
07-25-2007 · EurekAlert!
Hundreds of thousands of babies around the world are born each year with HIV -- more than half a million in 2006 alone. Now the initial results of an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Disease suggests, that more HIV-infected infants survive if they are given therapy early on, regardless of their apparent state of health.
Similar news · Read more »
